Stage Slip from Diagnostic Latency in MCED Trials: A Calibrated Monte Carlo Reconstruction of the NHS-Galleri Results

BackgroundThe NHS-Galleri trial reported a substantial reduction in Stage IV cancer diagnoses and a four-fold increase in cancer detection rates, but did not meet its primary endpoint of reducing combined Stage III+IV diagnoses in a prespecified group of 12 cancers. We hypothesize that stage slip-- progression of cancers from Stage I/II to Stage III during diagnostic workup--is the primary mechanism behind this statistical masking. MethodsWe developed a Monte Carlo simulation of 142,000 participants (matching NHS-Galleri enrolment) across 12 cancer types, calibrated to NHS England population stage distributions. The model represents three competing clocks: biological sojourn times, screeninginitiated or symptom-driven pathway initiation, and diagnostic infrastructure delays. The median standard-of-care diagnostic delay (92 days) was constructed from five convergent evidence streams. We estimated the number of intervention-arm cases where a cancer was biologically Stage I/II but recorded as Stage III+IV at diagnosis, and determined how many such cases would need to be recovered for the composite endpoint to reach statistical significance. We validated that the 12 deadly cancers produce a sufficiently large early-stage patient pool and confirmed robustness across a wide range of test sensitivity and diagnostic delay assumptions. FindingsThe calibrated control arm reproduces NHS stage distributions within 1-2 percentage points for all 12 cancers. In the intervention arm, we estimate 84 cases of stage slip (95% CI: 68-104) at published sensitivity values. If only 25 of these cases (approximately one in three) had been diagnosed before crossing the Stage II/III boundary, the composite endpoint would have reached p < 0.05 at reported sensitivity levels. The slip count is robust to sensitivity assumptions, varying from approximately 74 to 85 cases across a 30-100% range of published CCGA 3 values. Across diagnostic delays from 65 to 120 days (at realised sensitivity), the estimate ranges from approximately 55 to 95 cases. The expected pool of early-stage cancers in the 12 deadly types ([~] 260-335 screen-detected Stage I/II cases per arm) is large enough that even a 12% slip rate--corresponding to the most optimistic delay assumption--produces sufficient slippage to exceed the significance threshold. InterpretationStage slip provides a quantitatively sufficient and mechanistically transparent explanation for the primary endpoint miss. The tests biological performance is intact: it detects cancers earlier and reduces Stage IV diagnoses. The composite endpoint was attenuated by systemic diagnostic latency in the NHS, not by a failure of the assay. Future MCED trials should consider endpoints less vulnerable to infrastructure delays or incorporate prespecified adjustments for expected diagnostic pathway timing. FundingNone. RegistrationNot applicable.